Dried Blood Spot Collection Cards Market Size, Key Players and Regional Outlook, 2027–2034
REPORT DETAILS
Dried Blood Spot Collection Cards Market Summary
The global dried blood spot collection cards market is estimated at USD 428.55 million in 2026 and is projected to reach USD 451.44 million in 2027, expanding to USD 665.46 million by 2034 at a CAGR of 5.7% during 2027–2034. Dried blood spot cards let people collect a few drops of blood at home and post them to a lab, with no cold chain needed. Newborn screening, remote clinical trials and at-home testing kits are driving use.
Market Statistics
Key Takeaways
• The Whatman 903 segment holds the largest share, an estimated 40.4% of revenue in 2026, owing to its established use in newborn screening.
• Cellulose-Based Filter Paper dominates the material segment, with a supplied estimate of 86.70% of global market revenue in 2026, supported by established newborn screening protocols, absorbency, and compatibility with laboratory analysis.
Newborn Screening holds the largest reported application share, estimated at 25.80% of global revenue in 2026, supported by government-led neonatal screening programmes and early detection of metabolic and genetic disorders.
• Decentralised trials use dried blood spots to avoid clinic visits.
• North America holds the largest regional share, at an estimated 35.3% in 2026, backed by newborn-screening programmes.
• Asia Pacific is expected to be the fastest-growing region, currently at an estimated 24.6% share, as screening programmes expand.
• A few filter-paper and diagnostics companies dominate.
Dried blood spot testing (DBS) is a minimally invasive blood sample gathering procedure on specifically designed filter paper. These DBS samples could be easily shipped to any lab to detect any hereditary, rare disease, or blood-related disorder.
The key factors responsible for the market growth of dried blood spot collection cards include compulsory newborn screening programs in developed economies, innovations in the diagnosis time and effectiveness, and the rising prevalence of hereditary disorders across the globe. In November 2019, the Virginia Department of General Services tested 7,868 infants for approximately 31 genetic and metabolic disorders. As per the estimates of the National Institutes of Health (NIH), more than 30 million people in the U.S. are suffering from around 7,000 hereditary diseases which are driving the demand for dried blood spot collection cards.

Know more about this report: Download Sample Report
Industry Dynamics
Growth Drivers
The dried blood spot collection method is vital in newborn screening to diagnose congenital diseases in infants. For instance, in November 2018, the state government of Pennsylvania introduced newborn screening (NBS) programs for the mandatory tests of serious hereditary disorders such as maple syrup urine disease (MSUD), adrenal hyperplasia, Pompe’s disease, X-linked Adreno-leukodystrophy, galactosemia, and mucopolysaccharidosis type 1.
The usage of DBS for the serological diagnosis of infectious and autoimmune diseases also driving the market. According to the World Health Organization (WHO), in 2018, there were around 37.9 million people diagnosed with HIV. In the same year, around 770,000 people were died from HIV, across the globe.

Know more about this report: Download Sample Report
Moreover, the use of DBS offers early and effective diagnosis, facilitating easy gathering and storage of samples and it is highly effective in plasma-based testing in low resource laboratory settings. Several counties in the U.S. have implemented DBS HIV testing, for instance, New South Wales (NSW) health ministry, in 2016, introduced DBS based HIV testing project, to improve penetration of HIV testing. This project aimed to eliminate HIV, by 2022, with increased adoption of DBS based diagnosis techniques.
Dried Blood Spot Collection Cards Market Report Scope
The dried blood spot collection cards industry report is primarily segmented on the basis of type, application, and region.
| By Type | By Application | By Region |
|
|
|
Source: Polaris Market Research Analysis
Know more about this report: Download Sample Report
Insight by Type
Based on card type, the global dried blood spot collection cards market is categorized into Whatman 903, Ahlstrom 226, FTA, and others. Whatman 903 dried blood spot collection cards industry segment accounted for the largest market share globally, in 2019. These are a safe and efficient method for sampling, gathering, and transport. Several firms, including, Eastern Business Forms Inc., is a U.S.-based manufacturer of newborn screening devices, is a renowned provider of “903 Five Spot Blood Card” across the globe. It is ready to use the product, which saves time and cost.
FTA dried blood spot collection cards industry segment is projected to register a lucrative growth rate over the forecast period. This is the new market entrant that allows rapid analysis and is usually combined with DNA preservation at room temperature, which facilitates the user with multiple copies from a single sample. Qiagen is the dried blood spot collection cards industry leader in the production of FTA Classic Card with varied applications such as drug discovery, molecular biology, forensics, plasmid screening, and STR analysis.
Insight by Application
Based on application, the dried blood spot collection cards market is segmented into forensics, therapeutic drug monitoring, newborn screening, infectious disease testing, and other applications. The newborn screening market segment for dried blood spot collection cards industry holds the majority of share during the assessment period, owing to its numerous benefits such as low cost, reproducibility, easy storage and gathering, short diagnosis period, and its high precision, in comparison to other collection techniques.
Moreover, the growing incidence of HIV is getting the attention of major dried blood spot collection cards industry players for easy and time-bound analysis of HIV. For instance, Roche Diagnostics offers a COBAS plasma separation product, which offers a collection device for HIV plasma and its storage. The therapeutic drug monitoring segment of the dried blood spot collection cards industry is anticipated to register a lucrative growth rate over the dried blood spot collection cards industry study period. DBS tags offer home or remote sampling, which is well suited for several drug classes such as anti-depressants, analgesics, antimalarials, anticonvulsants, antiretrovirals, and antibiotics.
Geographic Overview
North American dried blood spot collection cards industry accounted for the largest market share and is likely to maintain its dominance over the market study period. This high share is due to compulsory newborn screening (NBS) in both the U.S. and Canada. As per the statistics published by the National Institute of Children’s Health Quality, in 2016, NBS was performed in more than 4 million newborns in the U.S. alone, with a participation rate of higher than 99.99 percent. Center for Disease and Control (CDC) reported that each year around 12,500 infants were diagnosed with at least one chronic hereditary disease.
Moreover, several collaborations are being taken by the U.S. government to speed up newborn screenings. For instance, in 2016, the National Institute for Children's Health Quality developed the NewSTEPs 360 program, which undertook initiatives to improve testing in 20 states of the U.S. in collaboration with the Association of Public Health Laboratories and the Colorado School of Public Health. The project received funding of USD 5.4 million from the Health Resources and Services Administration (HRSA).
The growth in the European dried blood spot collection cards industry is expected to increase with rising cases of hepatitis B in the market. According to the Center for Disease, Prevention, and Control, in 2017, there were around 26,907 individuals diagnosed with the concerned disease, with a prevalence rate of 6.7 cases per 100,000. DBS is considered an important tool in the diagnosis of hepatitis B, as compared to conventional collection methods and it is easier to transport samples. Thus, a rise in hepatitis B cases will enable higher adoption of DBS driving the market demand for dried blood spot collection cards industry.
Competitive Insight
- Qiagen
- PerkinElmer
- Roche Diagnostics
- Shimadzu (Novilytic Labs)
- Ahlstrom-Munksjö
- Pall Corporation
- Eastern Business Forms Inc.
- ARCHIMEDlife
- Centogene AG.
The dried blood spot collection cards industry players in the market are introducing new products and services to remain competitive. For instance, in June 2019, Ahlstrom and GenTegra introduced the DBS collection card, which protects the DNA collected for around 20 years, without any contamination or damage.
Recent Developments
- In September 2026, Revvity announced the launch of its GSP T1D 3plex kit, a CE-IVDR certified automated multiplex assay to support population-wide screening for type 1 diabetes risk. The solution utilizes capillary dried blood spot samples along with Revvity’s GSP platform to expand the use of DBS-based screening technologies beyond traditional newborn screening programs. ( Source: Revvity)
- In 2026, Ahlstrom and Hamilton announced a partnership to develop automated dried blood spot sample processing by combining Ahlstrom’s specimen collection materials with Hamilton’s easyPunch STAR platform. The collaboration is centered on automating the punching of the cards and increasing sample traceability and laboratory throughput for applications like newborn screening, nutrigenomics and veterinary diagnostics. (Source: Ahlstrom)
Dried Blood Spot Collection Cards Market FAQ's
The dried blood spot collection cards market is valued at USD 428.55 million in 2026 and is expected to reach USD 451.44 million in 2027 and USD 665.46 million by 2034, according to Polaris Market Research.
The dried blood spot collection cards market is projected to grow at a CAGR of 5.7% from 2027 to 2034, adding roughly USD 214.02 million in value over the forecast period.
Dried blood spot cards let people collect a few drops of blood at home and post them to a lab, with no cold chain needed. Newborn screening, remote clinical trials and at-home testing kits are driving use.
The main applications are newborn screening, clinical trials, therapeutic drug monitoring, and infectious disease testing. At-home testing and decentralised trials expand use.
Download Sample Report of Dried Blood Spot Collection Cards Market
Please fill out the form to request a customized copy of the research report.